Cargando…

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies. Cancer stem cells (CSCs), which are not targeted by current therapies, may be the reason for pronounced therapy resistance. A new treatment option in phase II trials is cabozantinib that inhibits the pancreatic CSC surfac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hage, C, Rausch, V, Giese, N, Giese, T, Schönsiegel, F, Labsch, S, Nwaeburu, C, Mattern, J, Gladkich, J, Herr, I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674365/ https://www.ncbi.nlm.nih.gov/pubmed/23661005 http://dx.doi.org/10.1038/cddis.2013.158

Ejemplares similares

Enrichment of c-Met(+) tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib
por: Liu, L, et al.
Publicado: (2014)

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine
por: Isayev, Orkhan, et al.
Publicado: (2014)

Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation
por: Liu, Li, et al.
Publicado: (2014)

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
por: LABSCH, SABRINA, et al.
Publicado: (2014)

Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication
por: Forster, Tobias, et al.
Publicado: (2014)

Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
por: Zhang, Yiyao, et al.
Publicado: (2015)

Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP-1
por: Liu, Li, et al.
Publicado: (2017)

Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl
por: Nwaeburu, Clifford C., et al.
Publicado: (2016)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

Cabozantinib Inhibits Photodynamic Therapy-Induced Auto- and Paracrine MET Signaling in Heterotypic Pancreatic Microtumors
por: Broekgaarden, Mans, et al.
Publicado: (2020)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer
por: Abukiwan, Alia, et al.
Publicado: (2018)

Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer
por: Abukiwan, Alia, et al.
Publicado: (2023)

Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells
por: Kaczorowski, Adam, et al.
Publicado: (2016)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib
por: Gupta, Ajay, et al.
Publicado: (2020)

Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization
por: Zhang, Xiaoli, et al.
Publicado: (2020)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
por: Sachkova, Anastasia A., et al.
Publicado: (2022)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer
por: Nwaeburu, Clifford C., et al.
Publicado: (2017)

Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer
por: Nwaeburu, Clifford C., et al.
Publicado: (2023)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma
por: Beckermann, B M, et al.
Publicado: (2008)

Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10
por: Stern, Louisa, et al.
Publicado: (2018)

Hypoxia Induces EMT in Low and Highly Aggressive Pancreatic Tumor Cells but Only Cells with Cancer Stem Cell Characteristics Acquire Pronounced Migratory Potential
por: Salnikov, Alexei V., et al.
Publicado: (2012)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy
por: Fan, P, et al.
Publicado: (2016)

Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma
por: Karmacharya, Ujjwala, et al.
Publicado: (2021)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019)

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
por: Kim, Myeong Jin, et al.
Publicado: (2023)

MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells
por: De Bacco, Francesca, et al.
Publicado: (2016)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ilsvj6amrthk5h2co6g3c10cfb